12 Nov 2014

Transparency notification of Vanguard Health Care Fund

Read More
7 Nov 2014

UCB to sell its U.S. specialty generics business Kremers Urban to Advent International and Avista Capital Partners for US$ 1,525 million

Read More
28 Oct 2014

UCB enhances epilepsy presence in Japan and China: positive Phase 3 study for VIMPAT®

Read More
24 Oct 2014

UCB Interim Report for the first nine months of 2014: UCB continues the growth path

Read More
23 Sep 2014

Acquisition of own shares

Read More
16 Sep 2014

New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density

Read More
1 Sep 2014

New indication for VIMPAT® (lacosamide): UCB’s anti-epileptic drug approved by FDA as monotherapy in the treatment of patients with partial-onset seizures

Read More
1 Aug 2014

Transparency and Sharing: UCB Expands Access to Clinical Study Data

Read More
30 Jul 2014

UCB Half Year Report 2014: UCB: solid performance and pipeline delivery

Read More
23 Jul 2014

Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures

Read More
Subscribe to